Importantly, dominant negative type I or type II TGF-β receptors could partially reverse these metabolic abnormalities, highlighting TGF-β signaling as a potential target for mitigating insulin resistance (Hong et al., 2016). The gene discussed is TGFB1; the disease is Insulin resistance.